Szu-Han Chen

Mr. Szu-Han Chen

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2026 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
SCSzu-Han Chen
Szu-Han Chen
YTYu‐Wen Tseng
Yu‐Wen Tseng
CHChi‐Jung Huang
Chi‐Jung Huang
SYShu‐Mei Yang
Shu‐Mei Yang
MFMarat Fudim
Marat Fudim
HCHao-Min Cheng
Hao-Min Cheng
Aim: Heart failure with preserved ejection fraction (HFpEF) presents a therapeutic challenge, characterised by a paucity of validated treatments. Emerging data suggest that targeting adiposity is central to HFpEF pathogenesis. We conducted an updated network meta‐analysis to compare the efficacy of emerging and established HFpEF therapies. Materials and Methods: We systematically searched PubMed, Embase and Cochrane Library from inception to April 2025 for randomised controlled trials enrolling patients with HFpEF and evaluating pharmacotherapies, including angiotensin‐converting enzyme inhibitors, angiotensin receptor blockers, beta blockers, mineralocorticoid receptor antagonists (MRAs), digoxin, angiotensin receptor‐neprilysin inhibitor, sodium‐glucose transporter 2 inhibitors (SGLT2is), glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), nitrates and nitrites. The primary outcome was a composite of cardiovascular death and heart failure (HF) hospitalisation. The secondary outcomes included cardiovascular death, all‐cause mortality, worsening HF events, change in the 6‐min walk test (6MWT) distance, Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ‐CSS) and N‐terminal pro‐B‐type natriuretic peptide levels. A frequentist random‐effects NMA was conducted. Results: Thirty‐nine trials with 78 treatment arms and 48 235 patients were enrolled. Compared with placebo, GLP‐1 RAs (HR: 0.73, 95% CI 0.61–0.88) and SGLT2is (HR: 0.79, 95% CI 0.70–0.90; P‐score: 0.807) significantly reduced the risk of cardiovascular death and HF hospitalisation. GLP‐1 RAs showed the highest probability of ranking first (P‐score: 0.871). GLP‐1 RAs elicited the greatest improvement in functional outcomes, including the 6MWT (mean difference: +17.60 m, 95% CI 8.53–26.67) and KCCQ‐CSS (mean difference: +7.38 points, 95% CI 5.51–9.26). No statistically significant differences in cardiovascular death or all‐cause mortality were observed among the treatments. Conclusions: In patients with HFpEF, GLP‐1RA, SGLT2i and MRA significantly reduced the risk of cardiovascular death and HF hospitalisation, while GLP‐1RA additionally improved the functional and quality‐of‐life outcomes. GLP‐1RA and SGLT2i significantly reduced HF morbidity, and GLP‐1RA uniquely improved functional status, positioning adiposity modulation as a central therapeutic target in HFpEF.

30 September 2024 in Children
Verified
Journal Article
Open access
PDF file
MLMu-Yun Lin
Mu-Yun Lin
SCSzu-Han Chen
Szu-Han Chen
Jen-Ting LeeJen-Ting Lee
Jen-Ting Lee
PHPo-Cheng Hsu
Po-Cheng Hsu
Background: Pompe disease is a rare metabolic myopathy caused by the lack or deficiency of the lysosomal acid alpha-glucosidase, resulting in skeletal muscle weakness and cardiomyopathy. The disease varies by onset age and genetic mutations and is categorized into infantile-onset and late-onset Pompe disease. Respiratory muscle weakness may persist regardless enzyme replacement therapy. This systemic review and meta-analysis aim to assess the effect of respiratory muscle training (RMT) on respiratory muscle strength, functional endurance, and pulmonary function in patient with Pompe disease. Methods: PubMed, EMBASE, and Cochrane databases were searched up until Aug 2024. Studies examining the therapeutic effects of RMT in patients with Pompe disease were included. Outcome measures included the change in maximal inspiratory pressure (MIP), maximal expiratory pressure (MEP), six-minute walking test (6MWT), pulmonary function before after RMT, quality of life and adverse events. Results: The meta-analysis consisted of 5 single-arm studies, including 31 patients in total. Regarding inspiratory muscle strength, RMT has significantly improving MIP (8.71 cmH2O; 95% CI, 6.23–11.19, p < 0.001) and MEP (12.15 cmH2O; 95% CI, 10.55–13.74, p < 0.001) in both types of Pompe disease. However, no significant change regarding 6MWT. No serious adverse events were reported. Conclusions: Our meta-analysis revealed that RMT may increase inspiratory muscle and expiratory muscle strength, but may not have an effect on 6MWT in patients with Pompe disease. RMT has potential to be integrated into the cardioplulmonary rehabilitation for patients with Pompe disease. Further large randomized controlled trials are needed to verify the efficacy and safety of RMT in patients with Pompe disease.

4 August 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
SCSzu-Han Chen
Szu-Han Chen
YLYu‐Hsuan Lee
Yu‐Hsuan Lee
SCShao-Yuan Chuang
Shao-Yuan Chuang
MFMarat Fudim
Marat Fudim
CLChun-Wei Lee
Chun-Wei Lee
HCHao-Min Cheng
Hao-Min Cheng
Background: Obesity and systemic inflammation have each been independently associated with an increased risk of heart failure (HF). However, whether inflammatory pathways mediate the association between obesity and the development of heart failure remains unclear. Methods: We analyzed data from a community‐based cohort of 1998 participants to evaluate multiple adiposity indicators in relation to incident HF. hs‐CRP (high‐sensitivity C‐reactive protein) was examined as a mediator using causal mediation analysis to quantify the contribution of systemic inflammation. Kaplan–Meier analyses and multivariable Weibull accelerated failure time models were applied to estimate hazard ratios (HRs) for HF occurrence. Results: Over a median follow‐up of 6.9 years, individuals with elevated hs‐CRP levels showed significantly lower HF‐free survival (log‐rank P =0.010). In multivariable accelerated failure time models, indicators of central obesity and hs‐CRP—but not BMI—were significantly associated with higher HF risk (eg, waist circumference: HR=1.30 [95% CI: 1.05–1.61], P =0.017; hs‐CRP: HR=1.25 [1.05–1.51], P =0.013). Mediation analysis revealed that hs‐CRP accounted for 26.5% of the effect of waist circumference and 32.4% of the effect of waist‐to‐height ratio on HF risk, with statistically significant indirect effects for both. Conclusions: Our findings build upon recent conceptual advances by demonstrating that central obesity contributes to HF largely through inflammation. By quantifying the proportion of HF risk attributable to systemic inflammation, this study reinforces the rationale for prioritizing both anti‐obesity and anti‐inflammatory strategies in HF prevention.

1 September 2026 in Hypertension
Verified
Journal Article
Closed access
SCSzu-Han Chen
Szu-Han Chen
CYChih-Yu Yeh
Chih-Yu Yeh
YCYu-Pan Chiang-Lin
Yu-Pan Chiang-Lin
CHChi-Jung Huang
Chi-Jung Huang
SCShao-Yuan Chuang
Shao-Yuan Chuang
HCHao-Min Cheng
Hao-Min Cheng
BACKGROUND: Hypertension guidelines generally recommend uniform sodium restriction although determinants of salt sensitivity, or sodium-blood pressure responsiveness, remain incompletely quantified. We estimated the population sodium-blood pressure dose-response, identified clinical modifiers, quantified high salt sensitivity prevalence, and derived the number needed to restrict sodium intake to prevent 1 cardiovascular event across clinical strata. METHODS: PubMed, Excerpta Medica Database, and Cochrane were searched from inception to April 2025 for sodium intervention trials and observational studies. Blood pressure response was standardized per 50-mmol/d sodium difference. Random-effects meta-regression evaluated clinical modifiers. A highly salt-sensitive phenotype was defined a priori as a systolic blood pressure (SBP) decrease ≥3 mm Hg per 50-mmol/d reduction. RESULTS: We included 160 studies (255 estimates; n=16 443). Each 50-mmol/d higher urinary sodium excretion was associated with 1.76-mm Hg higher SBP (95% CI, 1.54–1.98). Age and baseline SBP were the strongest modifiers (0.41 mm Hg per 5 years; 0.23 mm Hg per 5 mm Hg). Salt-sensitive phenotype prevalence rose from 12.5% (age <40 years) to 56.5% (≥60 years) and from 16.3% (SBP <120 mm Hg) to 54.1% (≥130 mm Hg). Under a policy-relevant 100-mmol/d sodium reduction, number needed to restrict ranged from ≈1334 in younger, normotensive, lean individuals (age <60 years, SBP <130 mm Hg, and body mass index <25 kg/m 2 ) to ≈87 in older adults with hypertension and elevated body mass index (age ≥60 years, SBP ≥130 mm Hg, and body mass index ≥25 kg/m 2 ), a 15-fold gradient. CONCLUSIONS: Salt sensitivity varied across age, SBP, and body mass index strata. These findings suggest that routinely measured clinical characteristics may help identify populations with greater expected blood pressure response to sodium reduction.

18 August 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
SCSzu-Han Chen
Szu-Han Chen
HCHao-Min Cheng
Hao-Min Cheng

17 November 2026 in medRxiv
Verified
Preprint
Open access
SCSzu-Han Chen
Szu-Han Chen
YHYen Hsun Huang
Yen Hsun Huang
YLYu-Hsuan Lee
Yu-Hsuan Lee
SYShu-Mei Yang
Shu-Mei Yang
CHChi-Jung Huang
Chi-Jung Huang
HCHao-Min Cheng
Hao-Min Cheng
Background Mineralocorticoid receptor antagonists (MRAs) are standard therapy for primary aldosteronism (PA). Serum potassium is measured in nearly every treated patient, but the long-term prognostic value of potassium attained early after initiation is undefined. Methods In the TriNetX Research Network, we identified adults with PA newly initiating spironolactone or eplerenone in 2000-2025, without prior adrenalectomy (n=4,169; 180-day landmark design). Achieved potassium (last value on days 14-180) was categorised as <4.0, 4.0-<4.5, 4.5-<5.0 and ≥5.0 mmol/L, and its change from baseline in tertiles, using cause-specific Cox and Fine-Gray models. The primary outcome was a composite of myocardial infarction, stroke or death; incident heart failure was co-primary. Findings Over a median 3.0 years, 623 composite events occurred. Estimated risk was lowest at 4.5-<5.0 mmol/L (adjusted hazard ratio 0.65, 95% CI 0.52-0.83, versus <4.0 mmol/L), lower than the 4.0-<4.5 mmol/L band, and not different from ≥5.0 mmol/L. A larger rise in potassium was associated with lower risk. A similar pattern was seen for incident heart failure (0.54, 0.36-0.80; 248 events). Potassium below the 3.6 mmol/L consensus threshold for hypokalaemia carried no significantly higher risk (1.22, 0.96-1.56). The change in potassium correlated weakly with the change in renin (rho = 0.15). Interpretation In MRA-treated PA, cardiovascular and heart-failure risk was lowest at an early achieved potassium of 4.5-<5.0 mmol/L, well above the 3.6 mmol/L accepted by consensus criteria as correction of hypokalaemia; correction alone may therefore be an insufficient treatment target. Whether titrating therapy towards this band improves outcomes requires prospective evaluation.